Clinical Trial Update: 123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients

View source ↗

Summary

A completed clinical trial assessing whether 123I-BMIPP SPECT imaging can help reduce cardiac events in patients undergoing hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Coronary Artery Disease
• End-stage Renal Disease
• Ischemic Heart Disease

Drugs mentioned

• 123I-BMIPP (beta-methyl-p-iodophenyl-pentadecanoic acid radiolabeled with iodine-123)

Snippet

Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Conditions: Coronary Disease, Fatty Acids, Unsaturated | Status: COMPLETED